Published in Drug Week, August 12th, 2005
Forest Laboratories holds the marketing and development rights in the USA and Canada.
Desmoteplase, a novel plasminogen activator, or blood clot-dissolving agent, has the potential to treat patients with acute ischaemic stroke up to 9 hours after onset of symptoms. Ischaemic stroke is the most common type of stroke and occurs when an artery in the brain is obstructed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.